How eligible patient numbers affect price of rare disease drugs in France
Having recently assessed the relationship between drug price and prevalence of non-oncology rare diseases, CRA’s Cécile Matthews, Bhavesh Patel, and Owen Male explore in greater depth the situation for these orphan drug
France’s ATU reform: Early access remains possible, but not all diseases are equal
When France’s ATU reform was implemented, some viewed it as restrictive.
World Orphan Drug Congress Europe 2022
CRA is a proud sponsor of the congress.
Part 2: Low-priced oncology disruptors - The cuckoo in the PD-1/PD-L1 nest or the runt of the clutch?
Part II of this article was originally published in PharmaPhorum.
Part 1: Low-priced oncology disruptors - The cuckoo in the PD-1/PD-L1 nest or the runt of the clutch?
Part I of this article was originally published in PharmaPhorum.
2 years after Germany's regulation For digital health apps, what can we learn?
At the end of 2019, the Digital Healthcare Act (Digitales Versorgungsgesetz, DVG) introduced a dedicated pathway enabling reimbursement of digital health offerings in Germany, bringing more transparency into the approval process for manufacturers, physicians, and patients.
How does rare disease prevalence impact drug pricing in England?
This article was originally published in PharmaPhorum.